Results for Nucleic Acids ( 3456 )
- From: €7,284.00
DNA was prepared from cell line WM1799. WM1799 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4. WM1799 cells produce xenograft tumors when injected into immunocompromised mice.
- From: €2,175.00
Total RNA was prepared from cell line WM1799. WM1799 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4. WM1799 cells produce xenograft tumors when injected into immunocompromised mice.
- From: €3,630.00
Total RNA was prepared from cell line WM1799. WM1799 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4. WM1799 cells produce xenograft tumors when injected into immunocompromised mice.
- From: €7,284.00
Total RNA was prepared from cell line WM1799. WM1799 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4. WM1799 cells produce xenograft tumors when injected into immunocompromised mice.
- From: €2,175.00
DNA was prepared from cell line WM1819. WM1819 is a human melanoma cell line that displays mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1819 cells produce xenograft tumors when injected into immunocompromised mice.
- From: €3,630.00
DNA was prepared from cell line WM1819. WM1819 is a human melanoma cell line that displays mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1819 cells produce xenograft tumors when injected into immunocompromised mice.
- From: €7,284.00
DNA was prepared from cell line WM1819. WM1819 is a human melanoma cell line that displays mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1819 cells produce xenograft tumors when injected into immunocompromised mice.
- From: €2,175.00
Total RNA was prepared from cell line WM1819. WM1819 is a human melanoma cell line that displays mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1819 cells produce xenograft tumors when injected into immunocompromised mice.
- From: €3,630.00
Total RNA was prepared from cell line WM1819. WM1819 is a human melanoma cell line that displays mesenchymal morphology. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1819 cells produce xenograft tumors when injected into immunocompromised mice.